Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.
Multidrug resistance (MDR) is a major impediment to chemotherapy. In the present study, we designed antisense oligonucleotides (ASOs) against MDR1, MDR-associated protein (MRP)1, MRP2, and/or BCL-2/BCL-xL to reverse MDR transporters and induce apoptosis, respectively. The cationic liposomes (100 nm)...
Main Authors: | Yu-Li Lo, Yu Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3956467?pdf=render |
Similar Items
-
Correction: Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides
Published: (2014-01-01) -
Correction: Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides.
Published: (2014-01-01) -
Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2
by: Maria Gagliardi, et al.
Published: (2022-01-01) -
Cytotoxicity and reversal effect of sertraline, fluoxetine, and citalopram on MRP1- and MRP7-mediated MDR
by: Yuval Bin Kanner, et al.
Published: (2023-11-01) -
BCL-XL regulates the timing of mitotic apoptosis independently of BCL2 and MCL1 compensation
by: Chun Yin Yu, et al.
Published: (2024-01-01)